Dual Glucagon–GLP-1 Agonism (Survodutide) Produces Substantial Weight Loss in Obesity: NEJM| August 2026

Introduction:

GLP-1–based therapies have transformed obesity management, but additional metabolic pathways may further improve treatment. Survodutide is a once-weekly dual glucagon receptor and GLP-1 receptor agonist, designed to combine appetite reduction with glucagon-mediated effects on energy metabolism. The phase 3 SYNCHRONIZE-1 trial evaluated survodutide in adults with obesity or overweight with complications, but without diabetes.

Why was this study needed?

Obesity remains a chronic disease requiring effective long-term pharmacotherapy.

Some patients achieve inadequate weight loss or cannot tolerate existing GLP-1–based therapies.

Dual glucagon–GLP-1 agonism provides a mechanistically different approach to weight management.

Phase 3 evidence was required to establish efficacy and safety.

Results:

Among 725 participants, once-weekly survodutide produced approximately 12–13% mean weight loss at 76 weeks, compared with 5.4% with placebo plus lifestyle intervention.

More than 70% achieved ≥5% weight loss with either survodutide dose.

Increasing the dose from 3.6 mg to 6.0 mg produced relatively little additional average weight loss.

Gastrointestinal adverse effects were common and dose-related, particularly with 6.0 mg, but were generally mild to moderate; no deaths occurred.

Clinical Impact:

Survodutide establishes glucagon–GLP-1 dual agonism as another effective therapeutic strategy for obesity. The relatively modest incremental efficacy of 6.0 mg over 3.6 mg, despite greater gastrointestinal toxicity, highlights the importance of individualized dose optimization rather than automatically pursuing the highest dose.

Its glucagon activity is particularly interesting because survodutide is also being investigated for metabolic liver disease, potentially linking obesity treatment with liver-directed metabolic benefit.

Bottom Line:

Once-weekly survodutide achieved approximately 12–13% weight loss in adults with obesity without diabetes. Dual glucagon–GLP-1 agonism is an effective emerging obesity strategy, although gastrointestinal tolerability and the optimal dose–benefit balance will be important in clinical use.